Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

PRECISION MEDICINE IN RENAL TRANSPLANT PATIENTS - ROLE OF ABCG2 LOSS OF FUNCTION POLYMORPHISM (CROSBI ID 724227)

Prilog sa skupa u časopisu | sažetak izlaganja sa skupa | domaća recenzija

Borić Bilušić, Ana ; Božina, Nada ; Lalić, Zdenka ; Lovrić, Mila ; Nađ-Škegro, Sandra ; Penezić, Luka ; Barišić, Karmela ; Trkulja, Vladimir PRECISION MEDICINE IN RENAL TRANSPLANT PATIENTS - ROLE OF ABCG2 LOSS OF FUNCTION POLYMORPHISM // Pharmaca / Mršić-Pelčić, Jasenka ; Vitezić, Dinko ; Janković, Tamara (ur.). 2022. str. 121-121

Podaci o odgovornosti

Borić Bilušić, Ana ; Božina, Nada ; Lalić, Zdenka ; Lovrić, Mila ; Nađ-Škegro, Sandra ; Penezić, Luka ; Barišić, Karmela ; Trkulja, Vladimir

engleski

PRECISION MEDICINE IN RENAL TRANSPLANT PATIENTS - ROLE OF ABCG2 LOSS OF FUNCTION POLYMORPHISM

Introduction: Breast cancer resistance protein (BCRP/ABCG2) is an efflux transporter important in pharmacokinetics of a number of drugs. We evaluated effect of a loss-of-function polymorphism ABCG2 c.421C>A on exposure to mycophenolic acid (MPA) in stable adult renal transplant recipients of Croatian origin. Materials and methods: Patients (n=68 ; 43 co-treated with cyclosporine, 25 with tacrolimus) were genotyped for ABCG2 c.421C>A and 11 polymorphisms in genes encoding enzymes and transporters implicated in MPA pharmacokinetics. Donors were genotyped for polymorphisms suggested to affect renal MPA secretion. ABCG2 c.421C>A variant vs. wild-type (wt) patients were matched in respect to demographic, biopharmaceutic and genetic variables (full optimal combined with exact matching) and compared for dose-adjusted steady-state MPA pharmacokinetics (Frequentist and Bayes [skeptical neutral prior] estimates of geometric means ratios, GMR). Results: Raw data (12 variant vs. 56 wt patients) indicated by around 40% higher total exposure (frequentist GMR=1.45, 95%CI 1.10-1.91 ; Bayes = 1.38, 95%CrI 1.07-1.81) and by around 30% lower total body clearance (frequentist GMR=0.66, 0.58-0.90 ; Bayes=0.71, 0.53-0.95) in variant carriers than in wt controls. The estimates were similar in matched data (11 variant vs. 43 wt patients): exposure GMR=1.41 (1.11-1.79) frequentist, 1.39 (1.15-1.81) Bayes, with 85.5% probability of GMR >1.20 ; clearance GMR=0.73 (0.58-0.93) frequentist, 0.71 (0.54-0.95) Bayes. Raw data indicated exposure difference in tacrolimus-treated but not in cyclosporine-treated patients (P for genotype-calcineurin type interaction 0.045 frequentist, 92.7% Bayes). Conclusions: Loss-off-function polymorphism ABCG2 c.421C>A increases steady-state exposure to MPA in stable renal transplant patients. The effect might be conditional on the type of calcineurin inhibitor.

precision medicine, breast cancer resistance protein, transplant recipients, mycophenolic acid

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

121-121.

2022.

nije evidentirano

objavljeno

Podaci o matičnoj publikaciji

Pharmaca

Mršić-Pelčić, Jasenka ; Vitezić, Dinko ; Janković, Tamara

Zagreb:

0031-6857

Podaci o skupu

10. hrvatski kongres farmakologije ; 1. hrvatski kongres kliničke farmakologije s međunarodnim sudjelovanjem = 10th Croatian Congress of Pharmacology ; 1st Croatian Congress of Clinical Pharmacology and Therapeutics with International Participation

predavanje

22.09.2022-25.09.2022

Opatija, Hrvatska

Povezanost rada

Farmacija, Kliničke medicinske znanosti